{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:12:49Z","timestamp":1793913169812,"version":"4.8.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3705-7","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T14:09:24Z","timestamp":1510841364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed"],"prefix":"10.1186","volume":"17","author":[{"given":"Maureen","family":"Assayag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rouvier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghania","family":"Costel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Cluzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Mercadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Deray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Isnard Bagnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,16]]},"reference":[{"issue":"2","key":"3705_CR1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2015.05.005","volume":"89","author":"M Sassier","year":"2015","unstructured":"Sassier M, Dugu\u00e9 AE, Clarisse B, et al. Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting. Lung Cancer. 2015;89(2):161\u20136.","journal-title":"Lung Cancer"},{"key":"3705_CR2","first-page":"55","volume":"2","author":"O Gi-Su","year":"2014","unstructured":"Gi-Su O, So H-S, et al. Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolyte Blood Press. 2014;2:55\u201365.","journal-title":"Electrolyte Blood Press"},{"key":"3705_CR3","doi-asserted-by":"crossref","unstructured":"Ozkok A, Edelstein CL. Physiopathology of cisplatin-induced acute kidney injury. Biomed Res Int, Epub. 2014;","DOI":"10.1155\/2014\/967826"},{"key":"3705_CR4","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"21","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Gandara D, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;21:3543\u201351.","journal-title":"J Clin Oncol"},{"key":"3705_CR5","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.clinthera.2005.09.010","volume":"27","author":"KD Rollins","year":"2005","unstructured":"Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther. 2005;27:1343\u201382.","journal-title":"Clin Ther"},{"key":"3705_CR6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1586\/14737140.4.3.361","volume":"4","author":"LS Budde","year":"2004","unstructured":"Budde LS, Hanna NH. Pemetrexed (Alimta): improving outcome in malignant pleural mesothelioma. Expert Rev Anticancer Ther. 2004;4:361\u20138.","journal-title":"Expert Rev Anticancer Ther"},{"key":"3705_CR7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.seminoncol.2005.02.008","volume":"32","author":"MA Socinski","year":"2005","unstructured":"Socinski MA, Stinchcombe TE, Hayes DN, The evolving role of Pemetrexed (Alimta) in lung cancer. Semin Oncol. 2005;32:16\u201322.","journal-title":"Semin Oncol."},{"key":"3705_CR8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/07357900600629567","volume":"24","author":"JC Brandes","year":"2006","unstructured":"Brandes JC, Grossman SA, Ahmad H. Alteration of Pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature. Cancer Investig. 2006;24:283\u20137.","journal-title":"Cancer Investig"},{"key":"3705_CR9","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-11-0804","volume":"17","author":"J Blake-Haskins","year":"2011","unstructured":"Blake-Haskins J, Lechleider R, Kreitman R. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011;17:5858\u201366.","journal-title":"Clin Cancer Res"},{"key":"3705_CR10","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Quaggin S, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129\u201336.","journal-title":"N Engl J Med"},{"key":"3705_CR11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1385\/MO:23:3:419","volume":"3","author":"V Vootukuru","year":"2006","unstructured":"Vootukuru V, Liew YP, Nally JV Jr. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol. 2006;3:419\u201322.","journal-title":"Med Oncol"},{"key":"3705_CR12","doi-asserted-by":"crossref","unstructured":"Abbas, et al. Renal toxicities of targeted therapies. Targ Oncol. 2015; epub.","DOI":"10.1007\/s11523-015-0368-7"},{"key":"3705_CR13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14712\/fb2013059010015","volume":"59","author":"T Tesarova","year":"2013","unstructured":"Tesarova T. Proteinuria and hypertension in patients treated with inhibitors of the VEGF Signalling pathway \u2013 incidence, mechanisms and management. Folia Biol. 2013;59:15\u201325.","journal-title":"Folia Biol"},{"key":"3705_CR14","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","volume":"45","author":"Usui","year":"2014","unstructured":"Usui, et al. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factors inhibitors: a report of 5 cases and review of literature. Hum Pathol. 2014;45:1918\u201327.","journal-title":"Hum Pathol"},{"key":"3705_CR15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5414\/CN107921","volume":"82","author":"S Chauvet","year":"2014","unstructured":"Chauvet S, Courbebaisse M, Ronco P, Plaisier E. Pemetrexed induced acute kidney injury leading to chronic kidney disease. Clin Nephrol. 2014;82:402\u20136.","journal-title":"Clin Nephrol"},{"key":"3705_CR16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000208377","volume":"2","author":"J Michels","year":"2009","unstructured":"Michels J, Spano JP, Brocheriou I, Deray G, Khayat D, Izzedine H. Acute tubular necrosis and interstitial nephritis during Pemetrexed therapy. Case Rep Oncol. 2009;2:53\u20136.","journal-title":"Case Rep Oncol"},{"key":"3705_CR17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bulcan.2014.12.012","volume":"102","author":"H Izzedine","year":"2014","unstructured":"Izzedine H. Pemetrexed nephrotoxicity. Bull Cancer. 2014;102:190\u20137.","journal-title":"Bull Cancer"},{"issue":"3","key":"3705_CR18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.toxlet.2015.06.012","volume":"237","author":"T Karasawa","year":"2015","unstructured":"Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 2015;237(3):219\u201327.","journal-title":"Toxicol Lett"},{"key":"3705_CR19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.02780312","volume":"7","author":"Perazella","year":"2012","unstructured":"Perazella. Renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012;7:1713\u201321.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"3705_CR20","first-page":"49202","volume":"8","author":"SR Shah","year":"2015","unstructured":"Shah SR, Tunio SA, Jeoffrey SA, et al. Acute kidney injury recognition and management: a review of the literature and current evidence. Glob J Health Sci. 2015;8(5):49202.","journal-title":"Glob J Health Sci"},{"issue":"4","key":"3705_CR21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1054\/bjoc.2000.1643","volume":"84","author":"JG Wright","year":"2001","unstructured":"Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of glomerular filtration rate in cancer patients. Br J Cancer. 2001;84(4):452\u20139.","journal-title":"Br J Cancer"},{"key":"3705_CR22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2215\/CJN.07311009","volume":"5","author":"GS Markowitz","year":"2010","unstructured":"Markowitz GS, Nasr SH, Stokes MB, D\u2019Agati VD. Treatment with IFN-alpha, \u2212beta, or -gamma is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5:607\u201315.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"3705_CR23","first-page":"600","volume":"56","author":"K Harakura","year":"2014","unstructured":"Harakura K, Yokoo T, et al. A case of glomerulopathy associated with the vascular endothelial growth factor inhibitor bevacizumab. Nihon Jinzo Gakkai Shi. 2014;56(5):600\u20135.","journal-title":"Nihon Jinzo Gakkai Shi"},{"issue":"10","key":"3705_CR24","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1093\/ndt\/gft241","volume":"28","author":"M Airy","year":"2013","unstructured":"Airy M, Raghavan R, Truong LD, Eknoyan G. Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity. Nephrol Dial Transplant. 2013 Oct;28(10):2502\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"3705_CR25","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2169\/internalmedicine.54.3661","volume":"54","author":"K Maruyama","year":"2015","unstructured":"Maruyama K, Chinda J, Hasebe N, et al. Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib. Intern Med. 2015;54(7):823\u20136.","journal-title":"Intern Med"},{"key":"3705_CR26","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/JCO.2004.09.064","volume":"22","author":"R Kumasaka","year":"2004","unstructured":"Kumasaka R, Nakamura N, Shirato K, et al. Side effects of ther- apy: case 1. Nephrotic syndrome associated with gefitinib therapy. J Clin Oncol. 2004;22:2504\u20135.","journal-title":"J Clin Oncol"},{"key":"3705_CR27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/annonc\/mdp472","volume":"21","author":"EN Overkleeft","year":"2010","unstructured":"Overkleeft EN, Goldschmeding R, van Reekum F, et al. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol. 2010;21:184\u20135.","journal-title":"Ann Oncol"},{"key":"3705_CR28","first-page":"1","volume":"108","author":"YM Wang","year":"2015","unstructured":"Wang YM, Lee VW, et al. Adriamycin nephropathy in BALB\/c mice. Curr Protoc Immunol. 2015;108:1\u20136.","journal-title":"Curr Protoc Immunol"},{"issue":"suppl","key":"3705_CR29","first-page":"43","volume":"6","author":"SW Pitman","year":"1975","unstructured":"Pitman SW, Parker LM, Tattersall MHN, et al. Clinical trial of highdose methotrexate (NSC-740) with citrovorum factor (NSC-35%)-Toxicologic and therapeutic observations. Cancer Chemother Rep. 1975;6(suppl):43\u20139.","journal-title":"Cancer Chemother Rep"},{"key":"3705_CR30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.semnephrol.2010.09.005","volume":"30","author":"MA Perazella","year":"2010","unstructured":"Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention\/therapy. Semin Nephrol. 2010;30:570\u201381.","journal-title":"Semin Nephrol"},{"key":"3705_CR31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.2013.8638","volume":"310","author":"F Lapi","year":"2013","unstructured":"Lapi F, Azoulay L, Niazi MT, et al. Androgen deprivation therapy and risk of acute kidney injury in patients with pros- tate cancer. JAMA. 2013;310:289\u201396.","journal-title":"JAMA"},{"key":"3705_CR32","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/dji242","volume":"97","author":"D Schrag","year":"2005","unstructured":"Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst. 2005;97:1221\u20134.","journal-title":"J Natl Cancer Inst"},{"issue":"1\u20133","key":"3705_CR33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejphar.2012.09.010","volume":"696","author":"S Nakagawa","year":"2012","unstructured":"Nakagawa S, Masuda S. Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. Eur J Pharmacol. 2012;696(1\u20133):143\u201354.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"3705_CR34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/1078155212466421","volume":"19","author":"AJ Lomax","year":"2013","unstructured":"Lomax AJ, Hill PA, Ashley DM. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme. J Oncol Pharm Pract. 2013;19(4):365\u20138.","journal-title":"J Oncol Pharm Pract"},{"key":"3705_CR35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1345\/aph.1H635","volume":"41","author":"RK Barakat","year":"2007","unstructured":"Barakat RK, Singh N, Lal R, et al. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma. Ann Pharmacother. 2007;41:707\u201310.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"3705_CR36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/ndt\/gfn625","volume":"24","author":"SK Winn","year":"2009","unstructured":"Winn SK, Ellis S, Savage P, Sampson S, Marsh JE. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant. 2009 Feb;24(2):673\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"3705_CR37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.amjopharm.2007.12.011","volume":"5","author":"A Khurana","year":"2007","unstructured":"Khurana A. Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother. 2007;5:341\u20134.","journal-title":"Am J Geriatr Pharmacother"},{"key":"3705_CR38","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/MPA.0b013e31803155d8","volume":"34","author":"A Yamamoto","year":"2007","unstructured":"Yamamoto A, Naruse S, Ito M, et al. Acute tubulointerstitial ne- phritis associated with long-term gemcitabine therapy. Pancreas. 2007;34:378\u20139.","journal-title":"Pancreas"},{"key":"3705_CR39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/pat.32.3.166.170","volume":"32","author":"PA Hill","year":"2000","unstructured":"Hill PA, Prince HM, Power DA. Tubulointerstitial nephritis fol- lowing high dose ifosfamide in three breast cancer patients. Path- ology. 2000;32:166\u201370.","journal-title":"Path- ology"},{"key":"3705_CR40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/(SICI)1096-911X(199607)27:1<57::AID-MPO11>3.0.CO;2-2","volume":"27","author":"BJ Morland","year":"1996","unstructured":"Morland BJ, Mann JR, Milford DV, et al. Ifosfamide nephrotoxi- city in children: histopathological features in two cases. Med Pediatr Oncol. 1996;27:57\u201361.","journal-title":"Med Pediatr Oncol"},{"issue":"3","key":"3705_CR41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0002-9343(91)80022-E","volume":"90","author":"BR McDonald","year":"1991","unstructured":"McDonald BR, Mehta RL, et al. Acute renal failure associated with the use of intraperitoneal carboplatin : a report of two cases and review of literature. Am J Med. 1991;90(3):386\u201391.","journal-title":"Am J Med"},{"key":"3705_CR42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJM198401053100107","volume":"310","author":"SD Averbuch","year":"1984","unstructured":"Averbuch SD, Austin HA III, Sherwin SA, et al. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides. N Engl J Med. 1984;310:32\u20135.","journal-title":"N Engl J Med"},{"key":"3705_CR43","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/ndt\/gfk071","volume":"21","author":"SE Kennedy","year":"2006","unstructured":"Kennedy SE, Shrikanth S, Charlesworth JA. Acute granuloma- tous tubulointerstitial nephritis caused by intravesical BCG. Nephrol Dial Transplant. 2006;21:1427\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"3705_CR44","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/ndt\/gfh688","volume":"20","author":"A Fry","year":"2005","unstructured":"Fry A, Saleemi A, Griffiths M, et al. Acute renal failure following intravesicle bacille Calmette-Guerin chemotherapy for superficial carcinoma of the bladder. Nephrol Dial Transplant. 2005;20:849\u201350.","journal-title":"Nephrol Dial Transplant"},{"key":"3705_CR45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000168368","volume":"11","author":"A Modesto","year":"1991","unstructured":"Modesto A, Marty L, Suc JM, et al. Renal complications of intra- vesical bacillus Calmette-Guerin therapy. Am J Nephrol. 1991;11:501\u20134.","journal-title":"Am J Nephrol"},{"issue":"5","key":"3705_CR46","first-page":"612","volume":"56","author":"M Tomita","year":"2014","unstructured":"Tomita M, Ochiai M, Iehara N, et al. A case of thrombotic microangiopathy with glomerular subendothelial IgA deposition due to bevacizumab. Nihon Jinzo Gakkai Shi. 2014;56(5):612\u20137.","journal-title":"Nihon Jinzo Gakkai Shi"},{"issue":"18","key":"3705_CR47","first-page":"5858","volume":"17","author":"JA Blake-Haskins","year":"2011","unstructured":"Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic Microangiopathy with targeted cancer agents. Nephrology Dialysis Transplantation. 2011;17(18):5858\u201366.","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"3705_CR48","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","volume":"45","author":"J Usui","year":"2014","unstructured":"Usui J, Seshan SV, et al. Clinicopathological spectrum of kidney diseases un cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol. 2014;45(9):1918\u201327.","journal-title":"Hum Pathol"},{"issue":"11","key":"3705_CR49","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/imj.12261","volume":"43","author":"J Richmond","year":"2013","unstructured":"Richmond J, Gilbar P, Abro E. Gemcitabine induced thrombotic microangiopathy. Intern Med J. 2013;43(11):1240\u20132.","journal-title":"Intern Med J"},{"key":"3705_CR50","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","volume":"21","author":"H Izzedine","year":"2006","unstructured":"Izzedine H, IsnardBagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O, et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006;21:3038\u201345.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"3705_CR51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2515\/therapie\/2014020","volume":"69","author":"S Negrini","year":"2014","unstructured":"Negrini S, Durrbach A, Becquemont L. Sirolimus-related systemic thrombotic microangiopathy after renal transplantation. Therapie. 2014;69(2):175\u20137.","journal-title":"Therapie"},{"key":"3705_CR52","doi-asserted-by":"crossref","unstructured":"Izzedine H, Brocheriou I, Deray G, Rixe O. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant. 2007;22(5):22\u20131481.","DOI":"10.1093\/ndt\/gfl565"},{"key":"3705_CR53","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1526-0968.2003.00127.x","volume":"8","author":"JS Dlott","year":"2004","unstructured":"Dlott JS, Danielson CF, Blue-Hnidy DE, McCarthy L. Drug-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a concise review. Ther Apher Dial. 2004;8:102\u201311.","journal-title":"Ther Apher Dial"},{"issue":"13","key":"3705_CR54","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1316118","volume":"370","author":"D Hunt","year":"2014","unstructured":"Hunt D, Kavanagh D, Chandran S, et al. Thrombotic mocroangiopathy associated with interferon beta. N Engl J Med. 2014;370(13):1270\u20131.","journal-title":"N Engl J Med"},{"key":"3705_CR55","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1053\/j.ajkd.2004.12.017","volume":"45","author":"Z Al Aly","year":"2005","unstructured":"Al Aly Z, Philocet Ashley JM, Gellens ME, Gonzalez E. Thrombotic thrombocytopenic Purpura in a patient treated with Imatinib Mesylate: true association or mere coincidence? Am J Kidney Dis. 2005;45:762\u20138.","journal-title":"Am J Kidney Dis"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3705-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T01:30:52Z","timestamp":1750987852000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3705-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,16]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3705"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3705-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,16]]},"article-number":"770"}}